This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME: Berlin Saturday, June 28, 2025, 09:00 Hrs [IST] The Eur ...

Bengaluru: Biocon Biologics Ltd ., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd ., has ...

Patients had a small but nonsignificant survival advantage when continuing with anti-VEGF therapy in the second-line instead ...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...